Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "Where To Buy Sedatives"

Looking for quality documents?
external link icon
Repligen Announces Market Launch of OPUS® 80R, Reinforces Technology Leadership in Pre-Packed Chromatography
- First and only available 80 cm diameter pre-packed column to address large-scale clinical and commercial-scale manufacturing of biological drugs -
WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its next-generation OPUS® column, the OPUS 80R, which is the largest pre-packed column on the market and is suitable for late-stage clinical into commercial-scale manufacturing of biological drugs. OPUS columns are used in downstream manufacturing processes, to purify biologics including monoclonal antibodies, recombinant proteins, vaccines and gene therapies. The OPUS product line is the industry’s broadest and most scalable with packed bed volumes now ranging from 50 microliters to 150 liters. The groundbreaking OPUS 80R columns are being highlighted in a Technology Workshop on March 21 st at the BioProcess International West
external link icon
Repligen Provides Q2 FY2012 Corporate Update Regulatory Progress on SecreFlo™ and Record Sales of Bioprocessing Products
external link icon
Repligen Licenses Potential Treatment for Spinal Muscular Atrophy; Conference call scheduled for Friday, October 23rd, 8:30 a.m. EDT
external link icon
Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $120 million, and $250 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”). In addition, Repligen has granted the underwriters of the offering of Shares (the “Shares Offering”) a 30-day option to purchase up to an additional 207,000 Shares and the underwriters of the offering of Notes (the “Notes Offering”) a 13-day option to purchase up to $37.5 million aggregate principal amount of additional Notes solely to cover over-allotments. The sale of the Shares to the underwriters in the Shares Offering is expected to settle on July 19, 2019, subject to
publications icon
Validating Protein Concentration of Antibody-Drug Conjugates with the CTech™ SoloVPE® System
 UV-Vis spectroscopy is the simplest and most common method to determine protein concentration of ADCs; however, traditional fixed-pathlength spectrophotometers have issues. Authors: Nigel Herbert, Joshua Das, Priya Patel-Abbvie
external link icon
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Customers experience optimized facility equipment installation, footprint, and maintenance requirements WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) - Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell ® ATF upstream intensification technology into Sartorius’ Biostat STR ® bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers. The Biostat STR ® now contains a fully compatible embedded XCell ® ATF hardware and software module offering predefined advanced control recipes with integrated Process Analytical Technology (PAT). This system gives users a streamlined way to control cell growth and improve cell retention in perfusion processes without using a separate cell retention control tower.
external link icon
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines. The program has entered stage two, which is focused on both scaling up the manufacturing of this ligand, and on the development and validation of the related affinity chromatography resin. The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines. Repligen anticipates that the final resin product will be commercially available in early 2021. Ralf Kuriyel, Repligen Senior Vice President
external link icon
Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options
WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1,587,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $138.1 million, and $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”), which includes the exercise in full of the underwriters’ option to purchase 207,000 additional Shares and $37.5 million additional Notes. The offering of the Shares (the “Shares Offering”) is expected to result in approximately $130.7 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen. The offering of the Notes (the “Notes Offering” and,
external link icon
Repligen Announces Acquisition of Chromatography Technology Platform "Plug and Play" Products Create Broad Opportunity in Biopharmaceutical Manufacturing
publications icon
Continuous Bioprocessing: Current Practice And Future Potential Publication
E-book Volume 1 2014 Compiled by John Bonham-Carter, Repligen Chapters Introduction to Continuous Manufacturing:Technology Landscape and Trends Eric S. Langer and Ronald A. Rader, BioPlan Associates A Brief History of Perfusion Biomanufacturing Jerry Shevitz and John Bonham-Carter, Refine Technology Bioreactor Configuration and Operation Christel Fenge, Jörg Weyand, Gerhard Greller, Thorsten Adams, Sartorius Stedim Biotech How to Develop a Perfusion Process Véronique Chotteau, Royal Technical University, KTH Case Study: Optimized Perfusion Shaun Eckerle, Gallus BioPharmaceuticals Process Intensification Approaches for Cost Sensitive Protein Applications Willem Adriaan de Jongh, Expres2ion Biotechnologies Impact of Single-use Technology on Continuous Biorocessing William G. Whitford, Thermo Fisher Scientific Continuous Multicolumn Chromatography Processes Marc Bisschops, Tarpon Biosystems Continuous Processes: Economic Evaluation Andrew Sinclair and Andrew Brown, BioPharm Services Vision: Integrating Upstream and Downstream in a Fully Continuous Facility Tim Johnson, Genzyme